Tracking and Evaluating Molecular Tumor Markers With Cancer Registry Data: HER2 and Breast Cancer
- 28 April 2014
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (5)
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyChemotherapy Research and Practice, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesJournal of Clinical Oncology, 2011
- Incidence of Breast Cancer in the United States: Current and Future TrendsJNCI: Journal of the National Cancer Institute, 2011
- Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) programBreast Cancer Research and Treatment, 2008
- Breast Cancer Heterogeneity: A Mixture of At Least Two Main Types?JNCI: Journal of the National Cancer Institute, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987